Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Israel-Hamas war
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    Most Read
    • Military briefing: How Israel is attacking Hamas’s vast tunnel network
    • Chinese borrowers default in record numbers as economic crisis deepens
    • US funding for Ukraine set to run out by end of the year, White House warns
    • US warship and commercial vessels attacked in Red Sea, says Pentagon
    • EU budget dispute threatens €50bn war lifeline for Ukraine
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Ex-Freshfields partner ‘highly likely’ to be convicted in tax scandal
      • UBS sells Credit Suisse jet used by Horta-Osório during Covid breaches
      • Spotify to cut almost a fifth of staff in efficiency drive
      • How to deal with Europe’s zombie banks
      • Saudi Arabia buys 49% of Rocco Forte’s luxury hotel chain
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Wealth Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • The real impact of the ESG backlash
      • News updates from December 4: Spotify and Telefónica slash jobs, Qatar cuts stake in Barclays
      • Bitcoin price surges above $42,000 as rate cut bets fuel cross-asset rally
      • Gold price hits all-time high as traders bet on interest rate cuts
      • Qatar slashes stake in Barclays with £510mn share sale
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • America and a crumbling global order
      • US CEOs start to contemplate Trump, round 2
      • Island strife: Greece serves Germany a dose of its own medicine 
      • Why Modi is cruising to a third term
      • EU must stand up for Taiwan at China summit
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      • Working It
      Most Read
      • Why staff loyalty is not always a good thing
      • Friederike Otto: ‘The climate backlash is the last attempt by those who don’t want change’
      • Amy Edmondson wins FT and Schroders Business Book of the Year
      • Are workplace romances a savvy investment?
      • How alcohol became a crutch for professional women
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • The FT’s 25 most influential women of 2023
      • Three Iranian women fighting for artistic freedom
      • Chess: Hans Niemann playing in London this week amid new controversy
      • In search of the real Nelson Mandela
      • 48 hours in Tokyo
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Hannah Kuchler

    Global Pharmaceutical Editor

    Hannah Kuchler is the global pharmaceutical editor for the Financial Times. She was part of the FT’s team reporting on the Covid-19 pandemic, which received an honourable mention at the SABEW awards for its coverage.

    She was previously the US pharma and biotech correspondent based in New York, where she collaborated with PBS Frontline on a documentary about the opioids crisis, which was nominated for an Emmy and won a Loeb award.

    Other roles have included over five years as a technology correspondent covering social media and cyber security in San Francisco.

    Email Hannah Kuchler @hannahkuchler  on Twitter (link opens in a new browser window)

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Tuesday, 5 December, 2023
      News in-depthNovo Nordisk AS
      Novo Nordisk seeks to use obesity drug findings to prevent weight gain

      Pharma group behind blockbuster drug wants to supersize its market impact

      3 hours ago
      Lotte Bjerre Knudsen, chief scientific adviser at Novo Nordisk, works in the lab
    • Friday, 1 December, 2023
      Pfizer Inc
      Pfizer drops plan for twice-daily obesity pill due to side effects

      Decision is setback for US drugmaker looking to increase sales after pandemic

      A man walks past the Pfizer headquarters in New York City
    • Wednesday, 29 November, 2023
      Ageing Populations
      Science prize targets health advances for ageing societies

      Non-profit offers $101mn for discoveries that will restore muscle, brain and immune functions

      An elderly Chinese man on a bicycle
    • Monday, 27 November, 2023
      Novo Nordisk AS
      Novo Nordisk looks at flexible pricing for obesity drug

      Danish pharma group in talks with healthcare providers about innovative models to boost Wegovy take-up

      Lars Fruergaard Jørgensen
    • Wednesday, 22 November, 2023
      AstraZeneca PLC
      AstraZeneca fights accusations its Covid-19 jab was ‘defective’

      Vaccine recipient claims he suffered side effect of severe blood clot

      A health worker prepares a dose of the AstraZeneca Covid-19 vaccine
    • Thursday, 16 November, 2023
      Medical science
      UK approves Crispr gene editing therapy in global first

      Regulator authorises treatment for sickle cell disease and beta thalassaemia

      A scientist at Vertex Pharmaceuticals
    • Wednesday, 15 November, 2023
      FT SeriesTech Champions
      Airfinity gives decision makers big picture on health

      Covid may have abated, but emerging diseases and new drug categories are keeping the analytics firm busy

      Portrait of Airfinity founder Rasmus Bech Hansen
    • Saturday, 11 November, 2023
      Novo Nordisk AS
      Novo Nordisk’s obesity drug cuts risk of death by 18%, trial data shows

      Wegovy found to have ‘quite profound’ effect on reducing risk of heart attacks, says pharma group

      A 0.25 mg injection pen of Novo Nordisk’s weight-loss drug Wegovy
    • Monday, 6 November, 2023
      BioNTech
      BioNTech cuts revenue forecast on lower demand for Covid jabs

      German group slashes guidance by €1bn and reduces spending as it expects fewer first vaccine doses and lower boosting

      A patient receiving a vaccine dose
    • Thursday, 2 November, 2023
      Moderna
      Moderna shares hit by quarterly loss and waning Covid vaccine demand

      Biotech blames weaker US sales after lowering full-year forecast

      Syringes with needles in front of Moderna’s logo
    • Thursday, 2 November, 2023
      Novo Nordisk AS
      Novo Nordisk’s sales of weight loss drugs soar

      Danish group has expanded manufacturing capacity but says demand will continue to outstrip supply

      A Wegovy injection pen on top of a box
    • Wednesday, 1 November, 2023
      GSK PLC
      GSK raises annual profit forecasts after strong vaccine sales

      First jab for respiratory syncytial virus powers sales at UK drugmaker

      A GSK R&D laboratory
    • Wednesday, 25 October, 2023
      Drugs research
      New studies find benefits in very early drug treatment of Alzheimer’s

      Pioneering medicines developed by Eisai and Eli Lilly shown to be more effective when taken earlier

      Screen showing brain patterns of an Alzheimer’s patient
    • Tuesday, 24 October, 2023
      Drug prices
      Pharmaceutical industry close to deal with UK on drug pricing, says Novartis

      Sector has been critical of government after sharp rise in clawback tax

      Bottles of Novartis’s Adakveo sickle cell medicine
    • Tuesday, 24 October, 2023
      Pharmaceuticals sector
      Novo Nordisk and Eli Lilly hoover up smaller obesity drug groups

      Biotech acquisitions this year intended to cement position as market leaders in weight-loss field

      A Wegovy weight-loss drug injection pen
    • Monday, 23 October, 2023
      AstraZeneca PLC
      AstraZeneca hails ‘clinically meaningful’ cancer drug trial results

      Drugmaker upbeat on full data after initial findings disappointed investors

      AstraZeneca logo on its building in Macclesfield, England
    • Monday, 23 October, 2023
      Drugs research
      Roche agrees $7.1bn deal for Telavant to boost drug pipeline

      Swiss pharma group acquires rights to develop and manufacture bowel disease treatment

      A Roche sign on the side of the company’s headquarters in Basel, Switzerland
    • Wednesday, 18 October, 2023
      Pharmaceuticals sector
      EU and UK regulators warn fake diabetes drug found at wholesalers

      It follows surge in popularity of Ozempic, which is often used for weight loss

      Packets of Ozempic, which is sold by Danish drugmaker Novo Nordisk
    • Tuesday, 17 October, 2023
      Pensions industry
      UK venture capitalists explore ways to boost pension fund investment

      Proposed ‘Venture Capital Compact’ would include pledge to look at fund structure to address pension industry concerns

      Dame Kate Bingham
    • Tuesday, 17 October, 2023
      Disease control and prevention
      Global warning system essential to beat future pandemics, says Cepi chief

      Call for rapid detection comes as pharma groups criticise draft WHO treaty on how to avoid another health crisis

      Richard Hatchett
    • Monday, 16 October, 2023
      BioNTech
      BioNTech writes down €900mn on Covid-19 vaccines

      Biotech group hit by lower demand, with majority of write-offs relating to raw materials bought during pandemic

      A dose of the BioNtech/Pfizer Covid vaccine is administered to a person at a vaccination centre
    • Monday, 16 October, 2023
      News in-depthFood & Beverage
      Predictions that weight-loss drugs will dampen appetite hard to swallow for snacks makers

      Analysts anticipate that Ozempic and Wegovy will hurt sales at some groups as patients reduce calorie intake

    • Sunday, 15 October, 2023
      Merck & Co Inc
      Merck to open £1bn London research centre with plea for government support of industry

      Drugmaker praises country’s scientific expertise but says it must address conflicts in areas such as drug pricing

      MSD’s new facility in King’s Cross
    • Friday, 13 October, 2023
      Novo Nordisk AS
      Novo Nordisk raises profit guidance as weight-loss drug sales boom

      Danish drugmaker behind Wegovy and Ozempic has become Europe’s biggest company

      A Wegovy injection
    • Wednesday, 11 October, 2023
      GSK PLC
      GSK settles 4 Zantac cases to head off trial threat

      UK drugmaker reaches agreement in US over cases tied to allegations heartburn medicine causes cancer

      The GSK logo on the exterior of the company’s building
    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookie PolicyManage CookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsProfessional SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on XFT ChannelsFT Schools

    Tools

    PortfolioToday’s Newspaper (FT Digital Edition)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Israel-Hamas war
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
      • Artificial intelligence
      • Semiconductors
      • Cyber Security
      • Social Media
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Wealth Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      • Working It
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • Visual and data journalism
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today’s Newspaper (FT Digital Edition)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In